<SEC-DOCUMENT>0001493152-20-004952.txt : 20200521
<SEC-HEADER>0001493152-20-004952.hdr.sgml : 20200521
<ACCEPTANCE-DATETIME>20200327172849
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001493152-20-004952
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20200327

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RITTER PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001460702
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				263474527
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		1880 CENTURY PARK EAST, SUITE 1000
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90067
		BUSINESS PHONE:		310-203-1000

	MAIL ADDRESS:	
		STREET 1:		1880 CENTURY PARK EAST, SUITE 1000
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90067
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-family: Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 45; width: 180"></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">599
        Lexington Avenue</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">New
        York, NY 10022-7650</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">+1
        212 521 5400</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fax
        +1 212 521 5450</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">reedsmith.com</FONT></P></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
27, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>VIA
EDGAR</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
and Exchange Commission</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Division
of Corporation Finance</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100
F Street, N.E.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington,
D.C. 20549</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Ms. Ada D. Sarmento and Ms. Celeste Murphy</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ritter
    Pharmaceuticals, Inc.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amendment
    No. 1 to Registration Statement on Form S-4</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed
    March 13, 2020</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>File
    No. 333-236235</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Ms. Sarmento and Ms. Murphy:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
behalf of our client, Ritter Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;), we submit this letter in response to comments
from the staff (the &ldquo;Staff&rdquo;) of the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) contained in
its letter dated March 24, 2020 (the &ldquo;Comment Letter&rdquo;), relating to the above-referenced Amendment No. 1 to Registration
Statement on Form S-4 (the &ldquo;Amended Registration Statement&rdquo;). We are concurrently filing via EDGAR this letter and
Amendment No. 2 to the Registration Statement (the &ldquo;Second Amended Registration Statement&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below in bold are comments from the Comment Letter. For your convenience, each of the numbered paragraphs below corresponds
to the numbered comment in the Staff&rsquo;s Comment Letter and includes the caption used in the Comment Letter. Immediately following
each comment is the Company&rsquo;s response to that comment, including, where applicable, a cross-reference to the location of
changes made in the Second Amended Registration Statement in response to the Staff&rsquo;s comment. All page references in the
responses set forth below refer to page numbers in the Second Amended Registration Statement. Defined terms used but not otherwise
defined herein have the meanings ascribed to such terms in the Second Amended Registration Statement.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">Securities
                                         and Exchange Commission</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">March
27, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Page
2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Amendment
No. 1 to Registration Statement on Form S-4</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Background
of the Transaction, page 93</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -34pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
    note your revised disclosure in response to our prior comment 3 and reissue in part. Please disclose which members of the
    Board were consulted to determine which candidates would receive an initial draft of the letter of intent.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has revised the disclosures on page
94 of the Second Amended Registration Statement to provide the information requested by this comment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>ALAN
(AS1411-GNP), page 170</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -34pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
    note your response to our prior comment 14. Please revise the discussion of the royalty term for the ULRF agreement to disclose
    when the last to expire of the licensed patents is currently expected to expire. We note your revised disclosure that the
    ACT License Agreement terminates on November 26, 2033, unless earlier terminated under certain circumstances. Please clarify
    whether the royalty term under this agreement has the same duration.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -34pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has revised the disclosures on page
170 of the Second Amended Registration Statement to provide the information requested by this comment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Regulatory
Strategy, page 171</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
                                         note your revised disclosure in response to our prior comment 16 that accelerated FDA
                                         approval is often granted prior to completion of a randomized Phase 3 trial if a new
                                         drug produces no safety signals of great concern and if a validated biomarker for patient
                                         selection has been established and is readily available. Please substantiate this statement.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has removed the statement that &ldquo;accelerated
FDA approval is often granted prior to completion of a randomized Phase 3 trial if a new drug produces no safety signals of great
concern and if a validated biomarker for patient selection has been established and is readily available&rdquo; from the Second
Amended Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Intellectual
Property, page 173</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
                                         note that there are several patents which expire during 2020 and 2021. Please disclose
                                         any material consequences to your business, as applicable, if the patents expire in accordance
                                         with the current expiration dates.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has revised the disclosures on page
173 of the Second Amended Registration Statement to provide the information requested by this comment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
and Exchange Commission</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
27, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
3</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Unaudited
Pro Forma Condensed Combined Financial Statements </U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Notes
to the Unaudited Pro Forma Condensed Combined Financial Information </U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Note
3: Pro forma adjustments, page 214</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
                                         have reviewed your response to prior comment 22 and your revised disclosure in adjustment
                                         (e). Please explain to us how you determined that the Ritter Series Alpha preferred stock
                                         should not be accounted for as a liability under ASC 480, nor classified as temporary
                                         equity. </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that the Ritter Series Alpha preferred stock
will be classified as permanent equity, based on the terms of the preferred stock. In order to determine the appropriate classification
for the Ritter Series Alpha preferred stock, we first analyzed the instrument pursuant to the criteria in ASC 480-10-25. Under
ASC 480, an issuer would classify a financial instrument that is within its scope as a liability (or an asset in some circumstances)
because that financial instrument embodies an obligation of the issuer. The following instruments should be classified as a liability
based on the criteria in ASC 480-10-25:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mandatorily
    redeemable financial instruments issued in the form of shares,</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligations
    that require or may require repurchase of the issuer&rsquo;s equity shares by transferring assets (e.g., written put options
    and forward purchase contracts), and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    obligations to issue a variable number of shares where at inception the monetary value of the obligation is based solely or
    predominantly on:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 94.5pt; text-align: justify; text-indent: -22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    fixed monetary amount known at inception, for example, a payable settlable with a variable number of the issuer&rsquo;s equity
    shares,</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Variations
    in something other than the fair value of the issuer&rsquo;s equity shares, for example, a financial instrument indexed to
    the S&amp;P 500 and settlable with a variable number of the issuer&rsquo;s equity shares, </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Variations
    inversely related to changes in the fair value of the issuer&rsquo;s equity shares, for example, a written put option that
    could be net share settled.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Ritter Series Alpha preferred stock is not mandatorily redeemable, nor does it require the Company to repurchase the shares issued
(1 and 2, above). The Ritter Series Alpha preferred stock is not convertible into a variable number of common shares with a fixed
monetary amount at inception (3a); conversion is only tied to the variations in fair value of the Company&rsquo;s equity shares
(3b) and, there is no inverse relationship with changes in the Company&rsquo;s equity (3c). Based on our above analysis, the Ritter
Series Alpha preferred stock is not a liability within the scope of ASC 480.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Next,
we assessed whether the preferred stock should be classified in either permanent equity or mezzanine equity based on the guidance
in ASC 480-10-S99 (ASR 268). ASR 268 requires that a redeemable equity instrument is not to be included in permanent equity. Rather,
it should be reported between long-term debt and stockholders&rsquo; equity, without a subtotal that might imply it is a part
of stockholders&rsquo; equity (i.e., &ldquo;temporary equity&rdquo; or &ldquo;mezzanine capital&rdquo;). ASR 268 specifies that
redeemable stock is any type of equity security, including common or preferred stock, which has any of the following characteristics:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
    is redeemable at a fixed or determinable price on a fixed or determinable date or dates,</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
    is redeemable at the option of the holder, or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
    has any condition for redemption which is not solely within the control of the issuer without regard to probability.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
and Exchange Commission</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
27, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
4</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series Alpha preferred stock is not unconditionally redeemable. The Series Alpha preferred stock is conditionally
redeemable only upon a Liquidation Event, which is defined as &ldquo;any liquidation, dissolution or winding-up of the Corporation,
whether voluntary or involuntary.&rdquo; A Liquidation Event, as defined, does not include certain deemed liquidation events that
are often seen in other preferred stock instruments, such as upon a change of control. ASC 480-10-25-4 specifically excludes instruments
redeemable only upon the liquidation or termination of the reporting entity: &ldquo;A mandatorily redeemable financial instrument
shall be classified as a liability unless the redemption is required to occur only upon the liquidation or termination of the
reporting entity.&rdquo; ASR 268 contains similar guidance in ASC 480-10-S993A(f): &ldquo;Ordinary liquidation events, which involve
the redemption and liquidation of all of an entity&rsquo;s equity instruments for cash or other assets of the entity, do not result
in an equity instrument being subject to ASR 268.&rdquo; As the Series Alpha preferred stock is neither unconditionally
redeemable nor conditionally redeemable, other than in an ordinary liquidation, the Series Alpha preferred stock is classified
in permanent equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>In
    addition, you refer to a 5% commitment fee in adjustment (e), but you disclose 162,424,242 common shares on the cover page
    and 162,340,584 common shares on page 232 as it relates to the conversion of the Series Alpha preferred stock. Please revise
    to clearly explain how these common share numbers relate to the 5% equivalent. </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that the disclosure of 162,424,242 common shares
on the cover page is incorrect. The disclosure of 162,340,584 common shares on page 232, as it relates to the conversion of the
Series Alpha preferred stock, is correct. The share amount on the cover page has been corrected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
disclosure of 162,340,584 common shares on page 232, as it relates to the conversion of the Series Alpha preferred stock, is presented
without giving effect to the pro forma estimated one-for-25 Ritter Reverse Stock Split. The disclosed amount represents
the aggregate Qualigen Series Alpha preferred stock estimated to be issued in connection with the Pre-Closing Qualigen Financing,
which will be converted into the right to receive the same number of shares of Series Alpha preferred stock of the combined company
which will be convertible into 6,493,623 shares of common stock of the combined company, subject to a &ldquo;blocker&rdquo; provision,
after giving effect to the pro forma estimated one-for-25 Ritter Reverse Stock Split. This share amount is comprised of
three components, each of which is disclosed in the revised adjustment (e) in Note 3, Pro forma adjustments, to the unaudited
pro forma condensed combined financial statements included in the Second Amended Registration Statement, after giving effect
to the pro forma estimated one-for-25 Ritter Reverse Stock Split:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Qualigen Series Alpha preferred stock issued pursuant to the Pre-Closing Qualigen Financing described in the Financing Commitment
    Letter dated January 15, 2020, as amended, for $4.0 million in cash proceeds, will be exchanged in the merger for Ritter Series
    Alpha preferred stock, which will be convertible into 4,846,294 shares of common stock of the combined company. </FONT></TD></TR>
</TABLE>

<P STYLE="font-family: Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
and Exchange Commission</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
27, 2020</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
5</FONT></P>



<P STYLE="font-family: Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Financing Commitment Letter provides that, for the commitment to fund the Pre-Closing Qualigen Financing, the Investor will
    receive a commitment fee from Qualigen equivalent to 5% of the issued and outstanding Ritter common stock as of immediately
    after the Closing on a fully diluted basis. Such commitment fee will be paid in Qualigen Series Alpha preferred stock and
    will be exchanged in the merger for Ritter Series Alpha preferred stock, which will be convertible into 1,211,573 shares of
    common stock of the combined company.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    the Financing Commitment Letter, the Investor also agreed to, at or before Closing, convert the principal and accrued interest
    on all debt owed to it by Qualigen into shares of Qualigen common stock, at the conversion price set forth in such existing
    debt instruments, or into the Qualigen Series Alpha preferred stock issued in the Pre-Closing Qualigen Financing. Of the $1.4
    million in Qualigen convertible notes payable and $0.177 million of accrued interest payable to the Investor as of December
    31, 2019, Qualigen and the Investor have agreed that the first $350,000 of the debt will be converted into Qualigen Series
    Alpha preferred stock and the remainder of the debt will be converted into Qualigen common stock. The Qualigen Series Alpha
    preferred stock issued to the Investor will be exchanged in the merger for Ritter Series Alpha preferred stock, which will
    be convertible into 435,756 shares of common stock of the combined company. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
                                         revise adjustment (e) to provide more details of the 1% common stock warrant. For example,
                                         disclose how and when the warrant strike price will be determined. Provide an estimated
                                         range of the fair value of the warrant. Disclose whether there will be a one time expense
                                         for the issuance and the reason it is not necessary to reflect the expense in the pro
                                         forma statements of operations as it is non-recurring.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has revised the disclosure of adjustment
(e) in Note 3, Pro forma adjustments, to the unaudited pro forma condensed combined financial statements included in the Amended
Registration Statement to provide more details of the 1% common stock warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qualigen
has entered into a financing commitment letter with the Investor to sell to the Investor shares of Qualigen Series Alpha preferred
stock (and associated warrants) for at least $4 million in cash no later than immediately prior to the Effective Time (the &ldquo;Pre-Closing
Qualigen Financing&rdquo;). The consummation of the Pre-Closing Qualigen Financing is a condition to the merger.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants to be issued to the Investor of the Pre-Closing Qualigen Financing, pursuant to the Financing Commitment Letter dated
January 15, 2020, as amended, will have a fixed strike price and fixed notional value upon their issuance, determined on the close
of the merger. The Investor will be issued Qualigen common stock warrants exercisable for a number of shares of Qualigen common
stock that will represent, after assumption of the warrants by Ritter in the merger and adjustments of the warrants to reflect
the Exchange Ratio, warrants to purchase a number of shares of Ritter common stock that is, as of immediately after the merger,
1% of Ritter&rsquo;s fully-diluted common stock. Pursuant to the Financing Commitment Letter, the warrants will have a (pre-merger)
strike price of no less than a 50% premium over the conversion price of Qualigen Series Alpha preferred stock. The conversion
price of Qualigen Series Alpha preferred stock is to be established by a pre-money valuation of $16.0 million for Qualigen, and
the warrants strike price is contemplated to be exactly 150% of the conversion-price amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
and Exchange Commission</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
27, 2020</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
6</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair value of the Qualigen common stock warrants is approximately $121,000, based upon a preliminary valuation of the
combined company utilized in the Pre-Closing Qualigen Financing of $16.0 million. Inputs used to determine the estimated
fair value of the common stock warrants include: risk free rate &ndash; 1.69%, expected volatility &ndash; 69.0%, effective life
- 5.0 years and dividend yield &ndash; N/A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial fair value of the Qualigen common stock warrants issued to the Investor of the Pre-Closing Qualigen Financing is a direct
and incremental cost of the Pre-Closing Qualigen Financing. The Qualigen Series Alpha preferred stock issued in the Pre-Closing
Qualigen Financing will be classified in permanent equity, as the Series Alpha preferred stock will not be a liability within
the scope of ASC 480 and will not be classified as temporary equity based on the guidance in ASC 480-10-S99. Direct and incremental
costs incurred to issue instruments classified in permanent equity are recognized as a reduction in the proceeds of the stock
(as a reduction of equity) and are considered a component of any premium or discount on the preferred stock. As such, there will
be no expense for the issuance of the Qualigen common stock warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
    have reviewed your response to prior comment 25 and the revised disclosure in adjustment (j). Please expand your disclosure,
    in tabular form, to quantify the number of shares that are excluded from pro forma diluted weighted average number of shares
    as their effect would be antidilutive. Also, provide on a separate line item of your pro forma weighted average shares table
    the 1,090,416 shares disclosed in adjustment (h).</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has revised the disclosure of adjustment
(j) in Note 3, Pro forma adjustments, to the unaudited pro forma condensed combined financial statements included in the Second
Amended Registration Statement to quantify the number of shares that are excluded from pro forma diluted weighted average
number of shares and to also provide a separate line item of our pro forma weighted average shares table for the 1,090,416 shares
disclosed in adjustment (h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
and Exchange Commission</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
27, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
7</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
    have reviewed your response to prior comment 26 and the revised disclosure in adjustment (h). Please clarify your disclosure
    to indicate that the amounts will be recorded as non-employee compensation in the period of the merger, as indicated in your
    response, and that the cost is not reflected in the pro forma statements of operations as it is nonrecurring.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has revised the disclosure of adjustment
(h) in Note 3, Pro forma adjustments, to the unaudited pro forma condensed combined financial statements included in the Second
Amended Registration Statement to indicate that the amounts will be recognized as non-employee compensation in the period
of the merger and that the cost is not reflected in the pro forma statements of operations as such costs are not expected to have
a continuing impact on the combined results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Ritter
Series Alpha Preferred Stock, page 216</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
    disclose the &ldquo;equity conditions&rdquo; covenants, as referred to under Liquidation Preference.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has revised the disclosures on page
217 of the Second Amended Registration Statement. The prior reference to &ldquo;equity conditions&rdquo; was made in error.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
    revise your disclosure to more clearly describe how the number of common shares to be issued will be determined upon conversion
    of Ritter Series Alpha preferred stock.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has revised the disclosures on page
217 of the Second Amended Registration Statement to provide the information requested by this comment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Annual
Financial Statements of Qualigen, Inc. </U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Independent
Auditor&rsquo;s Report, page F-36</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
    have your auditor provide a revised report complying with AS 3101 regarding the format of audit reports and that confirms
    that their audit was performed in compliance with PCAOB standards.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0">The Company acknowledges
the Staff&rsquo;s comment and respectfully advises the Staff that the auditor&rsquo;s report will be  revised to comply with
AS 3101 in the next filing of an amendment to the Registration Statement on Form S-4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Notes
to Financial Statements </U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>General,
page F-42</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
    have reviewed your response to prior comment 34 and the notes to the financial statements, but we have not identified any
    revised disclosure responsive to the prior comment. Please revise as necessary and clarify where you have provided the entity-wide
    disclosures required by ASC 280-10-50-40 through 50-42.</B></FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify">The Company acknowledges
the Staff&rsquo;s comment and respectfully advises the Staff that Qualigen has reviewed the entity-wide disclosures required by
ASC 280-10-50-40 through 50-42 and concluded that it operates in only one business segment. Such statement is included at the
end of the first paragraph of Note 1 to the audited financial statements included in the Second Amended Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>1.
Organization and Summary of Significant Accounting Policies </U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Net
Product Sales, page F-45</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
    have reviewed your response to prior comment 35 and note that you simply removed the references to distributor allowances
    rather than describing them as requested. Please clarify for us the basis for this revision. Confirm if true that you have
    not had any distributor allowances, or revise as previously requested to describe them.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0">The Company
acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that the original disclosures were revised in the
audited financial statements included in the Second Amended Registration Statement to remove the references to distributor
allowances as they were outdated. Qualigen does not have any distributor allowances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
                                         and Exchange Commission</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
27, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Page
8</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Research
and Licenses, page F-45</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
    have reviewed your response to prior comment 39 and do not note revised disclosure responsive to the comment. Please revise
    your disclosure to address how you account for research revenue when there is a possibility of contingent payments related
    to unsuccessful research and development activities, as referred to on page F-46 of your prior filing.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0">The Company acknowledges
the Staff&rsquo;s comment and respectfully advises the Staff that Qualigen is not a party to any R&amp;D agreements that include
the possibility of contingent payments related to unsuccessful research and development activities. The description in Note 2
at F-49 (F-46 in the original filing) has been corrected in the audited financial statements included in the Second Amended Registration
Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>5.
Equipment held for Lease, net, page F-50</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>16.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
    note your response to prior comment 41 and your determination that none of your arrangements meet the criteria for classification
    as a sales-type lease. Please explain to us in further detail how you considered ASC 840-10-25-1(c). In this regard, we note
    on page F-44 that your agreements are generally three years and the useful life of your medical equipment is three to five
    years. As part of your response, tell us the useful life you use for purposes of ASC 840, and explain to us in further detail
    how you determined this useful life. Explain to us how your product is used after it is returned to you in support of any
    useful life of greater than three years.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0">The Company
acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that Qualigen&rsquo;s agreements to provide
equipment and products to certain customers as part of a multiple element arrangement have a three-year term, and can
generally be renewed by the customer on a month-to-month basis upon expiration of the initial term. Qualigen has reviewed
these arrangements and has concluded that the non-cancelable lease terms are very short, as the customer can cancel the
entire purchase arrangement at any time with 30 days&rsquo; notice, return of the equipment, and payment of a small penalty.
As such, the lease component of these contracts would not qualify as a sales-type lease. If a customer decides to
terminate an arrangement, the equipment is returned to Qualigen, refurbished, and sold. In addition, the majority of this
equipment currently placed at customer locations is fully-depreciated. Rental revenues for the nine months ended December 31,
2019, and the years ended March 31, 2019 and 2018 were $0, $143,000, and $132,000 respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>12.
Research and License Agreements, page F-54</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
    have reviewed your response to prior comment 45, but do not note any revised disclosure responsive to the comment. We reissue
    the prior comment. Clarify your disclosure to more clearly identify the party that is providing the $7.2 million in future
    financing and the party that is receiving the financing, and the amount that has been provided to date. In addition, revise
    to clarify why you became liable to refund $500,000 and owe an additional $390,000 to Sekisui, as disclosed in Note 16 on
    page F- 65.</B></FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0 0 0 0.5in; text-align: justify">The Company acknowledges the Staff&rsquo;s comment and respectfully
advises the Staff that Qualigen extended its strategic partnership agreement in with Sekisui in October 2017 (see Note 12 at F-56)
in exchange for up to $7.2 million in future product development financing. As of both December 31, 2019 and March 31, 2019 Qualigen
had received a total of $5,520,000 under this agreement. This disclosure will be updated in the PCAOB compliant financial statements
to be included in the next filing of an amendment to the Registration Statement on Form S-4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify">See response
to Question 18 below for a discussion of the $500,000 advance and the $390,000 of additional costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
    have reviewed your response to prior comment 43 and we do not note any revised disclosure to address your prior reference
    to a contingent payment. In this regard, it appears that there is no more reference to the contingent payment. If true, confirm
    to us that no such contingent payment obligation exists. Please explain to us details regarding the contingent payments related
    to the partnership with Sekisui and also explain to us the basis for any disclosure that is provided or not provided in the
    filing regarding these contingent payments.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0">The Company acknowledges
the Staff&rsquo;s comment and respectfully advises the Staff that no contingent payment obligations to Sekisui exist. In March
2018, $500,000 was received by Qualigen as an R&amp;D advance from Sekisui, and is shown on Qualigen&rsquo;s balance sheets as
due to related party. In August 2018, Sekisui agreed to separately pay for certain additional costs of up to $400,000. In May
2019, both companies agreed to terminate the product development, at which time Qualigen became liable to Sekisui to repay the
$500,000 R&amp;D advance (see Note 15 on page F-64 and Note 16 on page F-65) plus Sekisui&rsquo;s payment for certain additional
costs totaling $392,353 (see Note 16 on page F-65) shown on Qualigen&rsquo;s December 31, 2019 balance sheet as accrued expenses-related
party. The total of $892,353 (plus 12% interest beginning in December 2019) is due in June 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
and Exchange Commission</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
27, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
9</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
it would expedite the review of the information provided herein, please do not hesitate to call the undersigned at (212) 549-0216.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
Wendy Grasso</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wendy
    Grasso</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cc:
Andrew J. Ritter, CEO of Ritter Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  U -4# 2(  A$! Q$!_\0
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M+273W.ELR&1$(OPH0X++^N7AJQMK3PIX>LK5$BCA\.Z3#Y**J(88M,MD.Q
MJA4D (4 ;3TX-?RK_P#!+7)_X*G?'(DDF72OC9),>29G3QIX< :0]9&"1H@9
MMQ"JJCA0*[,5BJV59GPY+ZQ7=+&X3#4YTIU)RIN<*%&#?LY-T[MS;BU%Z-7?
M-<\3@G)^%?$3PZ^D'#-<DPN$K\#Y#A.)^'<RPN&C1Q\?89YB</B:,\=!PQ59
M57'DJ^TKM3UBX\B@U_6U:F0[]Q8KDE-Y);)EFW<DGY0 H09X QT HIMJX=I
M6)D"QEQV4-O* ?@#G@45]Q*/+)KS;Z_:][2^MM='U6I_+L9NHE4=-TN=*<82
MW4)).#?G*'++YEENH_W'/X@I@_A7^:'_ ,$U !_P<*>%975/+B_:B^/$DLK(
MC;!]A\?!22PW -*8F+*>'CC8_,B$?Z-_Q?'Q8/@N^'P3F\#6WQ">2VCTF?XC
M6^LW?A5(6N(FO3=VN@ZGI>HS7'V=&-JL4^TLK+)A'(?^4[X!_P#!OK^UM\ O
MVXM-_;BT7]HCX'ZSXXL/B!XP^(C>$M9\ >*(O!_]I>-Y-:%SICQZ7XL3Q$+
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MWMXM:T[57T:[T"_MKJSED !_)C_P<:KX\_:*T'X9?MGV>DVDWPTT+XH_%O\
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M9-\2XG%I87=MH_B>?P4FCI;0VHD>V;Q+!K$UWMBWO]GNXHXG 18B&9Z_*?\
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M078NT1X \L#& F !L^[@ 8XI=B;M^Q=X7:'VC=MR&V[L9V[@#C.,@'&0***
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DKM/WK:7WMI>V@X*HS@ 9ZX &?KBBBB@:26B22[))+[DDC__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
